Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Since the proportion of language and attentional difficulties in patients with epilepsy is recognized, both in the literature and in the clinical experience of practitioners, it is appropriate to propose a complete speech-language assessment of oral language and attention.This study investigates these impairments through the taking of specific tests.
The general objective of this study is to observe possible oral language and attention disorders in children with epilepsy, by age and etiology of epilepsy.
The objective of this work is to study therapeutic apheresis (including plasma exchange and immunoadsorption) among french neuropediatric tertiary centers and to prove that this treatment modality is effective and well tolerated in pediatric neurology diseases.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Score in the different tests assessing oral language | Test assessing oral language :
The scores obtained in the various tests are organized into 7 classes: Class 1 = percentiles less than 7 : "pathological" zone Class 2 = 7 to 20 percentiles : "fragile" zone / "weak" zone Class 3 = 21 to 38 percentiles : "low standard" zone Class 4 = percentiles 39 to 62 : "median standard" zone / expected average results for age or grade level Class 5 = 63 to 80 percentiles : "higher standard" zone Classes 6 and 7 = respectively 81 to 93 percentiles and percentiles greater than 93 : zone with results well above the norm for age or grade level. | day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Score in the different tests assessing attention | Tests assessing attention :
The scores obtained in the various tests are organized into 7 classes: Class 1 = percentiles less than 7 : "pathological" zone Class 2 = 7 to 20 percentiles : "fragile" zone / "weak" zone Class 3 = 21 to 38 percentiles : "low standard" zone Class 4 = percentiles 39 to 62 : "median standard" zone / expected average results for age or grade level Class 5 = 63 to 80 percentiles : "higher standard" zone Classes 6 and 7 = respectively 81 to 93 percentiles and percentiles greater than 93 : zone with results well above the norm for age or grade level. |
Not provided
Inclusion criteria:
The subjects should :
Exclusion criteria:
Not provided
Not provided
Children with epilepsy followed by Dr COLMARD at the Montpellier hospital and university center
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Maxime colmard, résident | UH MONTPELLIER | Principal Investigator |
| Moritz-Gasser Sylvie | UH MONTPELLIER | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Uh Montpellier | Montpellier | 34295 | France |
NC
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000073376 | Epileptic Syndromes |
| D003147 | Communication Disorders |
| D004828 | Epilepsies, Partial |
| D004829 | Epilepsy, Generalized |
| D003141 | Communicable Diseases |
| ID | Term |
|---|---|
| D004827 | Epilepsy |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| day 1 |
| D019954 |
| Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
| D007239 | Infections |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |